New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026
Eisai and Biogen presented five-year Clarity AD long-term extension data for LEQEMBI (lecanemab) at CTAD 2026, showing benefits of continuous treatment accrue over time in early Alzheimer's disease. Lecanemab reduced the relative risk of progression to the next disease stage by 36% vs. ADNI natural-history data, and reduced progression to moderate or severe AD by 49%. Among low-tau patients treated early, 66% showed no decline on CDR-SB at five years and 62% showed improvement.
Key figures
- Drug Name
- lecanemab-irmb (LEQEMBI)
- Phase Of Trial
- Phase 3
- Lte participation
- 95%
- Core study enrollment
- 1795
- Aria e first 12 months
- 13.5%
- Low tau no decline cdr sb
- 66%
- Low tau improvement cdr sb
- 62%
- Patients five years continuous
- 351
- Relative risk reduction progression
- 36%
- Relative risk reduction moderate severe
- 49%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.